07:00 , Oct 18, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Muscular atrophy; muscular dystrophy Hexamethylene bis-acetamide inducible 1 (HEXIM1) Mouse studies suggest inhibiting HEXIM1 signaling could...